Meeting
2018 ASCO Annual Meeting
Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy.
Authors
Grey A Wilkinson
Oncolytics Biotech Inc., Calgary, AB, Canada
Grey A Wilkinson , Aine Piar , Christopher Resnyk , M. Jordan Humphrey , Keith Glendinning , Hue Tran , Romit Chakrabarty , Andres Gutierrez , Matthew C. Coffey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Inflammatory Signatures
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3089)
DOI
10.1200/JCO.2018.36.15_suppl.3089
Abstract #
3089
Poster Bd #
303
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A clinical AI-driven multiplex immunofluorescence imaging pipeline to characterize tumor microenvironment heterogeneity.
First Author: Dmitry Zarubin
Poster
2020 ASCO Virtual Scientific Program
First-in-human phase Ib study of ATRC-101, an engineered version of a patient-derived antibody targeting a tumor-restricted ribonucleoprotein complex.
First Author: Jonathan Eliot Benjamin
Poster
2019 ASCO Annual Meeting
Association of TGF-β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer.
First Author: Amir Mehrvarz Sarshekeh
Poster
2018 ASCO Annual Meeting
A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY‑318).
First Author: J. Randolph Hecht